Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal
Impact of the Mandibular Advancement Device on Sleep Apnea Syndrome During Discontinuation of Treatment With Continuous Positive Airway Pressure: Randomized Controlled Trial
University Hospital, Angers
40 participants
Mar 5, 2024
INTERVENTIONAL
Conditions
Summary
Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.
Eligibility
Inclusion Criteria4
- Patient accepting MAD treatment
- Patient with an apnea-hypopnea index (AHI) greater than 15 events per hour on the initial recording
- Patient with excessive daytime sleepiness during initial treatment (ESE>10)
- Patient treated for more than 12 months by CPAP with average compliance greater than 5 hours per night
Exclusion Criteria5
- Initial severe daytime sleepiness characterized
- OSAS with ≥ 5 central apneas per hour of sleep at baseline recording
- Previously diagnosed severe cardiac and/or respiratory pathology:
- Body mass index ≥ 35 kg/m2
- Known contraindication to OAM treatment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05939934